

# Chih-Hsi Scott Kuo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8765145/publications.pdf>

Version: 2024-02-01

24  
papers

242  
citations

1040056

9  
h-index

1058476

14  
g-index

26  
all docs

26  
docs citations

26  
times ranked

264  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung Cancer in Republic of China. <i>Journal of Thoracic Oncology</i> , 2021, 16, 519-527.	1.1	34
2	Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1541-1549.	1.9	28
3	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1158-1166.	1.9	17
4	Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. <i>International Journal of Cancer</i> , 2022, 150, 626-635.	5.1	16
5	Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. <i>BMC Cancer</i> , 2021, 21, 859.	2.6	15
6	The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. <i>Pharmaceuticals</i> , 2020, 13, 331.	3.8	14
7	The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma. <i>Biomedicines</i> , 2020, 8, 36.	3.2	14
8	First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110357.	3.2	12
9	Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. <i>Cancers</i> , 2022, 14, 977.	3.7	12
10	Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 232.	4.8	10
11	Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. <i>Targeted Oncology</i> , 2019, 14, 433-440.	3.6	9
12	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). <i>Vaccines</i> , 2021, 9, 689.	4.4	9
13	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. <i>Thoracic Cancer</i> , 2022, 13, 1888-1897.	1.9	8
14	Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study. <i>Thoracic Cancer</i> , 2019, 10, 1683-1691.	1.9	6
15	The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis. <i>Scientific Reports</i> , 2022, 12, 4398.	3.3	6
16	Cardiorespiratory coupling is associated with exercise capacity in patients with chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2021, 21, 22.	2.0	5
17	A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. <i>Oncology and Therapy</i> , 2021, 9, 489-503.	2.6	5
18	Bronchoscopic debulking for endobronchial malignancy: Predictors of recanalization and recurrence. <i>Thoracic Cancer</i> , 2015, 6, 722-730.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. <i>Thoracic Cancer</i> , 2019, 10, 2274-2281.	1.9	4
20	A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. <i>BMC Cancer</i> , 2021, 21, 309.	2.6	4
21	Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR mutant and EGFR wild type nonsquamous non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1648-1655.	1.9	3
22	Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. <i>Cancers</i> , 2022, 14, 316.	3.7	3
23	Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab. <i>Cancers</i> , 2022, 14, 3470.	3.7	3
24	Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease. <i>Medicina (Lithuania)</i> , 2021, 57, 1160.	2.0	1